AstraZeneca plc 12.8% Potential Upside Indicated by Liberum Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Liberum Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 8810 GBX on its stock. This indicates the analyst now believes there is a potential upside of 12.8% from the opening price of 7808 GBX. Over the last 30 and 90 trading days the company share price has increased 62 points and increased 845 points respectively. The 1 year high for the share price is 7948 GBX while the 52 week low is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 8,955.91 GBX and a 200 day moving average of 7,296.35. There are currently 306,129,738 shares in issue with the average daily volume traded being 1,901,199. Market capitalisation for LON:AZN is £102,727,282,141 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.

      Search

      Search